Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-2101 vaccine in advanced non-small cell lung cancer
NCT00104780Phase 2Unknown
- Sponsor
- Epimmune Inc.
- Start
- Dec 2004
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of OSE-2101 in non-small cell lung cancer (NSCLC), sponsored by Epimmune Inc.. Status: unknown.
02
Drugs
OSE-2101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00104780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104780.